Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials

Note: Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals, Inc.Disclosure: Dr de Bruin-Weller is a consultant/advisor for AbbVie, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi Genzyme, and UCB and has received grant/research support from Regeneron Pharmaceuticals and Sanofi Genzyme. Dr Simpson reports grants from Eli Lilly, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, and Regeneron Pharmaceuticals Inc and personal fees from Dermira, Eli Lilly, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, and Valeant. Dr Cork is an investigator and/or consultant for Astellas, Boots, Dermavant, Galapagos, Galderma, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L'Oréal, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals Inc, and Sanofi Genzyme. Dr Chen is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Drs Msihid, Eckert, and Bégo-Le Bagousse are employees and may hold stock and/or stock options in Sanofi. Dr Taniou is an employee of Altran Technology. Dr Gadkari was a full-time employee of Regeneron Pharmaceuticals Inc when this work was conducted, received salary and bonus from Regeneron Pharmaceuticals Inc, and is currently a full-time employee of Boehringer Ingelheim.The authors would like to thank Qiuyue Chen for contributions to this work. Medical writing/editorial assistance was provided by Grace Richmond, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Funding Information: Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals, Inc .